Medline’s Vantex Central Venus Catheter (CVC) has been on the market for over 20 years and features patented, broad-spectrum, antimicrobial technology that reduces risks of colonization to improve patient safety and help prevent costly central line-associated bloodstream infections (CLABSI). The Oligon Technology inside and outside of the catheter is comprised of silver, platinum and carbon black; which allows for a time-released antimicrobial for maximum efficacy during indwelling period. The 2020 ASA Practice Guidelines for CVC insertion recommend the use of silver/platinum/carbon-impregnated catheters over uncoated catheters for most effective CLABSI risk reduction. The Vantex CVC meets ASA guidelines using time-release silver ions extruded throughout the body of the catheter, internally and externally, to decrease risk of catheter-related blood stream infection (CRBSI). A link to that full study is below. Along with the clinical benefits of this product, Medline designed this product intuitively to include features such as: a pressure-rated catheter, pre-attached needleless valves to save clinicians time during setup, a soft tip catheter to reduce the risk of vessel perforation, clear extension lumens for better fluid path visualization, and easy-to-read lumen identification and gauge size on color-coded hubs.
Learn more at medline.com/infection-prevention/antimicrobial-central-venous-catheter/.
